Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TYK2 Inhibition in Granuloma Annulare (GA) and Cutaneous Sarcoidosis (CS): an Opportunity for Pathogenesis Directed Therapy

NCT06725264 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT06725264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06725264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TYK2 Inhibition in Granuloma Annulare (GA) and Cutaneous Sarcoidosis (CS): an Opportunity for Pathogenesis Directed Therapy
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2025
Completion date
June 30, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

granuloma annulare, sarcoidosis